The COVID19 pandemic reminded us of the challenges when new airway pathogens evolve, as no specific treatments or prevention strategies normally exist. Besides potentially new pathogens, we also struggle to treat several well-known airway infections, and acute respiratory infections are the third largest cause of deaths in the world, after heart disease and stroke. In the low-income countries, respiratory tract infections (viral and bacterial) are still by far the largest cause of death. Pneumonia is still the largest cause of death among children in the world, especially the low-income countries, with ~800.000 children (below 5 years of age) dying each year due to pneumonia. Due to development of antimicrobial resistance, many bacterial airway infections are difficult to treat successfully with traditional antibiotics.

We believe our technology can be used to successfully treat and prevent airway infections, as our SoftOx Inhalation Solution (SIS) has a very broad antimicrobial spectrum, meaning it eradicate all kinds of bacteria and viruses (and fungi) and no resistance develops. SIS has been shown safe to inhale in humans, and in animal infections model we see promising effect of SIS in lowering the pathogen loads/eradicating the infection.